Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice

INTRODUCTION: Oncogenic driver mutations activating EGFR, ALK, or BRAF in NSCLC predict sensitivity to specific tyrosine-kinase inhibitors (TKIs). We provide data on prevalence, treatment and survival of driver-mutation positive NSCLC in a predominantly Caucasian population in routine clinical pract...

Descripción completa

Detalles Bibliográficos
Autores principales: Faehling, Martin, Schwenk, Birgit, Kramberg, Sebastian, Eckert, Robert, Volckmar, Anna-Lena, Stenzinger, Albrecht, Sträter, Jörn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652823/
https://www.ncbi.nlm.nih.gov/pubmed/29100434
http://dx.doi.org/10.18632/oncotarget.20857

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652823/
https://www.ncbi.nlm.nih.gov/pubmed/29100434
http://dx.doi.org/10.18632/oncotarget.20857

Ejemplares similares